Monitor the November 12 reconvened meeting for vote results. Failure to pass the proposal could signal governance friction, but the adjournment itself is a procedural step with no direct financial impact.
Price Chart
Executive Summary
Tempest Therapeutics adjourned its reconvened special meeting of stockholders on October 14, 2026, because it lacked sufficient votes to approve a proposal to replace supermajority voting requirements and permit stockholder action by written consent. The meeting was reconvened and adjourned for the fourth time and will reconvene on November 12, 2026. The proposal requires 75% of votes cast, and management has engaged a proxy solicitation firm to secure adequate votes.
Key Facts
- Special meeting reconvened on October 14, 2026, and adjourned due to insufficient votes for the Proposal.
- Proposal requires affirmative vote of at least 75% of votes entitled to be cast.
- 11,004,101 shares (74.3% of 14,806,997 outstanding) were present, constituting a quorum.
- Meeting will reconvene on November 12, 2026.
- Company engaged Sodali & Co. as proxy solicitor to achieve quorum.
Financial Impact
No financial figures disclosed; procedural adjournment only.
Risk Factors
- Continued inability to secure 75% supermajority vote could delay governance changes.
- Extended special meeting process may signal shareholder discontent or low engagement.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-111026 |
| Document: 0001213900-26-111026-index-headers.html | 0001213900-26-111026 |
| Document: 0001213900-26-111026-index.html | 0001213900-26-111026 |
| Document: 0001213900-26-111026.txt | 0001213900-26-111026 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | DEF 14A | $0.5102 | awaiting T+20 | — | $0.5110 (−0.16%) |
Oct 20, 2026 7d ago | DEFA14A | $0.5282 | awaiting T+20 | — | $0.5110 (−3.26%) |
Oct 20, 2026 7d ago | 8-K | $0.5282 | awaiting T+20 | — | $0.5110 (−3.26%) |
Oct 19, 2026 8d ago | 8-K | $0.5762 | awaiting T+20 | — | $0.5110 (−11.32%) |
Oct 2, 2026 25d ago | EFFECT | $0.8112 | awaiting T+20 | — | $0.5110 (+37.01%) |
Sep 25, 2026 4w ago | S-3 | $0.8316 $0.5102 | ▲ +38.65% | ▲ +38.62% | $0.5110 (+38.55%) |
Sep 17, 2026 5w ago | 8-K | $0.9680 $0.6240 | ▼ −35.54% | ▼ −35.74% | $0.5110 (−47.21%) |
Sep 16, 2026 5w ago | DEFA14A | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5110 (−42.91%) |
Sep 16, 2026 5w ago | 8-K | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5110 (−42.91%) |
Sep 11, 2026 6w ago | Press Release | $0.8117 $0.7601 | ▲ +6.36% | ▲ +8.23% | $0.5110 (+37.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers